Optimization of EGFR mutation detection by the fully-automated qPCR-based Idylla system on tumor tissue from patients with non-small cell lung cancer
Metrics: PDF 2094 views | HTML 2370 views | ?
Marius Ilie1,2,3, Catherine Butori1,3, Sandra Lassalle1,2,3, Simon Heeke2, Nicolas Piton4, Jean-Christophe Sabourin4, Virginie Tanga3, Kevin Washetine1,3, Elodie Long-Mira1,2,3, Priscilla Maitre3, Nathalie Yazbeck2, Olivier Bordone3, Virginie Lespinet3, Sylvie Leroy5, Charlotte Cohen6, Jérôme Mouroux2,6, Charles Hugo Marquette2,5, Véronique Hofman1,2,3 and Paul Hofman1,2,3
1Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, FHU OncoAge, University Côte d’Azur, Nice, France
2IRCAN Inserm U1081/CNRS 7284, FHU OncoAge, University Côte d’Azur, Nice, France
3Hospital-related Biobank (BB-0033-00025), Pasteur Hospital, FHU OncoAge, University Côte d’Azur, Nice, France
4Department of Pathology, Rouen University Hospital, Rouen, France
5Department of Pulmonary Medicine and Thoracic Oncology, Pasteur Hospital, FHU OncoAge, University Côte d’Azur, Nice, France
6Department of Thoracic Surgery, Pasteur Hospital, FHU OncoAge, University Côte d’Azur, Nice, France
Paul Hofman, email: [email protected]
Keywords: NSCLC, EGFR, targeted therapy, optimization, PCR
Received: March 21, 2017 Accepted: September 19, 2017 Published: October 04, 2017
Treatment with EGFR inhibitors is limited to patients with advanced/metastatic non-small cell lung cancer who have known EGFR mutations. Currently, patient care has to respond to several imperatives to make these inhibitors broadly available to all patients; fast and accurate detection of EGFR mutations by a sensitive and specific standardized cost-effective method, easy-to-implement in settings with limited expertise in molecular diagnostics.
We evaluated the Idylla™ EGFR Mutation Assay (Biocartis) for the detection of EGFR mutations in archived formalin-fixed paraffin-embedded (FFPE) tumor samples from a series of 55 patients with lung adenocarcinoma and compared these results with those obtained by a pyrosequencing ISO-15189 accredited laboratory method. The comparison was made on both whole surgical tumor sections and on three artificially constructed small biopsies (~1 mm) from the same FFPE blocks. Cost-effectiveness and turnaround time comparison between the two methods was performed.
On both whole tissue sections and on biopsy cores, the Idylla™ and pyrosequencing had an agreement of 95% (52/55). The Idylla™ EGFR Assay produced results faster and more cost-effective than pyrosequencing.
The Idylla™ system showed a good sensitivity and was cost-saving in our setting. Because of the easy workflow, the Idylla™ system has the potential to expand EGFR testing to more pathology laboratories in a reliable and fast manner.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.